Topics

Hemispherx Biopharma makes headway in advancing flagship cancer drug Ampligen in 2018

23:30 EDT 1 Apr 2019 | Proactive Investors

Ampligen is being studied to treat nine types of cancer: renal cell carcinoma, melanoma, non-small cell lung cancer, ovarian, breast, colorectal, urothelial, prostate and pancreatic cancer

Original Article: Hemispherx Biopharma makes headway in advancing flagship cancer drug Ampligen in 2018

NEXT ARTICLE

More From BioPortfolio on "Hemispherx Biopharma makes headway in advancing flagship cancer drug Ampligen in 2018"

Quick Search

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Renal Cell Carcinoma
Renal cell cancer (renal adenocarcinoma or hypernephroma) is the most common type of kidney cancer in adults. More than 8 in every 10 (80%) kidney cancers diagnosed in the UK are this type.  In renal cell cancer the cancerous cells start in the lini...

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...